Dose-Escalated Versus Standard Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: Nine-Year Results of a Randomized Phase 2 Trial
International Journal of Radiation Oncology*Biology*Physics · 2026-07
DOI: 10.1016/j.ijrobp.2026.07.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-07. Verfasst von Haoyue Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/…. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Peking Union Medical College, National Cancer Center.
Abstract (Originalsprache)
PURPOSE: To compare the safety and efficacy of preoperative simultaneous integrated boost chemoradiation therapy (SIB-CRT) versus standard chemoradiation therapy (CRT) for locally advanced rectal cancer. METHODS AND MATERIALS: This prospective, randomized phase II trial (NCT02195141) enrolled patients with stage II/III rectal adenocarcinoma. Patients were randomly assigned (1:1) to CRT (50 Gy/25 fx to the pelvis) or SIB-CRT (50 Gy/25 fx to the pelvis with a simultaneous integrated boost of 56 Gy to PGTV and 60 Gy to lateral metastatic nodes if present). Radical surgery was planned 6-8 weeks after CRT. The primary endpoint was pathologic complete response (pCR) rate; secondary endpoints were disease-free survival (DFS), overall survival, metastasis-free survival, local control, cancer-specific survival, and toxicity. RESULTS: From August 2013 to February 2015, 106 patients were enrolled: 55 in the SIB-CRT group and 51 in the CRT group. Acute grade 3 toxicity occurred in 14.5% (SIB-CRT) and 19.6% (CRT) of patients, primarily manifested as radiation dermatitis. Curative treatment (radical surgery or watch-and-wait) was achieved in 89.1% (49/55) of SIB-CRT patients and 78.4% (40/51) of CRT patients (P = .135). After a median follow-up of 116.6 months, the SIB-CRT group showed superior 9-year outcomes in the intention-to-treat population: DFS (70.8% vs 47.4%; hazard ratio [HR], 0.46; P = .013), overall survival (74.3% vs 48.9%; HR, 0.43; P = .008), metastasis-free survival (70.8% vs 47.2%; HR, 0.48; P = .017), local control (87.1% vs 70.1%; HR, 0.40; P = .038) and cancer-specific survival (77.4% vs 57.2%, P = .027). Similar benefits were observed in the curative treatment cohort. The pCR rates were comparable (15.2% vs 18.4%, P = .695). Exploratory subgroup analysis showed that the survival benefit of SIB-CRT was statistically significant in patients who did not receive perioperative chemotherapy (9-year DFS, 70.8%; HR, 0.343; P = .014), whereas no additional benefit was observed in those receiving chemotherapy. CONCLUSIONS: Dose escalation through simultaneous integrated boost during neoadjuvant CRT translates into superior long-term survival outcomes. Despite comparable pCR rates, the intensified control of both local disease and micrometastases by SIB-CRT, coupled with its significant superiority within the chemotherapy-naive subgroup, likely contributed to these robust results. These findings establish dose escalation as a potent strategy for optimizing long-term cure in the modern management of locally advanced rectal cancer, particularly in chemotherapy-ineligible patients.
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union…
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen,…
- State Key Laboratory of Molecular Oncology and Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union…
- School of Medicine, Southern University of Science and Technology, Shenzhen, China. Electronic address: renh3@sustech.edu.cn.
Förderung
- National Natural Science Foundation of China
- Peking Union Medical College
- National Cancer Center
Zitieren
APA
Li, H., Wang, N., Xu, T., Zhang, W., Lu, N., Fang, H., Song, Y., Liu, Y., Chen, B., Qi, S., Jing, H., Wang, S., Li, Y., Zhou, H., Li, N., Zhang, W., Ren, H., Tang, Y., & Jin, J. (2026). Dose-Escalated Versus Standard Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: Nine-Year Results of a Randomized Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.07.004
Vancouver
Li H, Wang N, Xu T, Zhang W, Lu N, Fang H, et al. Dose-Escalated Versus Standard Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: Nine-Year Results of a Randomized Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.07.004
BibTeX
@article{Li2026,
author = {Li, Haoyue and Wang, Ningyu and Xu, Tongzhen and Zhang, Wenjue and Lu, Ningning and Fang, Hui and Song, Yongwen and Liu, Yueping and Chen, Bo and Qi, Shunan and Jing, Hao and Wang, Shulian and Li, Yexiong and Zhou, Haitao and Li, Ning and Zhang, Wenwen and Ren, Hua and Tang, Yuan and Jin, Jing},
title = {Dose-Escalated Versus Standard Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: Nine-Year Results of a Randomized Phase 2 Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
doi = {10.1016/j.ijrobp.2026.07.004}
}
EUVIMED